In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on ESSA Pharma (EPIX – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $5.30.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 15.3% and a 47.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Currently, the analyst consensus on ESSA Pharma is a Moderate Buy with an average price target of $8.00.
Based on ESSA Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1 million. In comparison, last year the company had a GAAP net loss of $2.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.